Ruben A. Mesa, MD

Articles

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

September 11th 2020

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis. 

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Mesa on Accrual Considerations in MPN Clinical Trials

August 17th 2020

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials. 

Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs

August 13th 2020

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10th 2020

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 3rd 2020

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Dr. Mesa on Rechallenging With JAK Inhibitor Therapy in MPNs

July 23rd 2020

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

Dr. Mesa on Recent Data With Momelotinib in MPNs and Myelofibrosis

July 17th 2020

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.

Dr. Mesa on Treatment Advancements Made in MPNs

April 16th 2020

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.

Dr. Mesa on New Trials and Agents in the Myelofibrosis Pipeline

February 12th 2020

Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.

Dr. Mesa on JAK Inhibitors in the Pipeline for Myelofibrosis

January 28th 2020

Ruben A. Mesa, MD, discusses the approval of fedratinib in myelofibrosis and other JAK inhibitors in the treatment pipeline.

Dr. Mesa on the Efficacy of Fedratinib in Patients With Myelofibrosis and Low Platelet Counts

January 16th 2020

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Dr. Mesa on the FDA Approval of Fedratinib in Myelofibrosis

August 16th 2019

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the FDA approval of fedratinib (Inrebic) in myelofibrosis.

Dr. Mesa on Incorporating MPN Guidelines into Clinical Practice

February 25th 2017

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses how community oncologists can incorporate the NCCN Guideline for Myeloproliferative Neoplasms (MPNs) into clinical practice.

Dr. Mesa on Upcoming Updates to NCCN Guideline for MPNs

December 3rd 2016

Ruben A. Mesa, MD, chair of Hematology, Mayo Clinic, discusses updates that are expected in 2017 to the NCCN Guideline for Myeloproliferative Neoplasms (MPNs).